Core Viewpoint - Yuheng Pharmaceutical stated that its product, Pravastatin Sodium Tablets, developed in collaboration with Daiichi Sankyo, was not selected in the 11th batch of centralized procurement [2] Group 1 - The 11th batch of centralized procurement involves key products related to the company [2] - The company responded to investor inquiries on an interactive platform regarding the procurement results [2]

Group 1 - The core point of the article is that Yuheng Pharmaceutical (002437.SZ) participated in the 11th batch of centralized procurement, but its main product, Pravastatin Sodium Tablets, developed in collaboration with Daiichi Sankyo, was not selected in the procurement process [2] Group 2 - The company responded to an investor inquiry on an interactive platform regarding its participation in the 11th batch of centralized procurement [2] - The specific product mentioned, Pravastatin Sodium Tablets, is significant to the company's portfolio but did not achieve selection in this round of procurement [2]

Core Viewpoint - Yuheng Pharmaceutical's stock has shown a significant increase this year, with a 40.96% rise, despite recent fluctuations in trading volume and net capital outflow [1][2]. Financial Performance - For the period from January to September 2025, Yuheng Pharmaceutical reported a revenue of 1.665 billion yuan, a year-on-year decrease of 10.36%. However, the net profit attributable to shareholders increased by 32.85% to 244 million yuan [2]. - The company has distributed a total of 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 14, Yuheng Pharmaceutical's stock price was 3.51 yuan per share, with a market capitalization of 7.883 billion yuan. The stock experienced a 2.03% increase during the trading session [1]. - The trading volume indicated a net outflow of 5.7995 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of November 10, the number of shareholders for Yuheng Pharmaceutical was 104,800, a decrease of 0.66% from the previous period. The average number of circulating shares per person increased by 0.85% to 20,038 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 66.3697 million shares, an increase of 35.1366 million shares from the previous period [3]. Business Overview - Yuheng Pharmaceutical, established on March 27, 2000, and listed on June 23, 2010, is primarily engaged in the production and sales of pharmaceuticals. Its main revenue sources include vitamin drugs (43.88%), cardiovascular drugs (28.00%), and orthopedic drugs (10.72%) [1].

证券日报网讯誉衡药业（002437）11月13日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司股东总数约10.48万户。 ...

Group 1 - The core viewpoint of the news is that Yuheng Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with a notable decrease in revenue but an increase in net profit [1][2]. - As of November 11, Yuheng Pharmaceutical's stock price remained unchanged, with a trading volume of 148 million yuan and a net financing outflow of 847,300 yuan [1]. - The company's financing balance is 371 million yuan, accounting for 4.94% of its market capitalization, which is above the 60th percentile of the past year [1]. Group 2 - For the period from January to September 2025, Yuheng Pharmaceutical reported a revenue of 1.665 billion yuan, a year-on-year decrease of 10.36%, while the net profit attributable to shareholders increased by 32.85% to 244 million yuan [2]. - The number of shareholders increased by 2.88% to 105,500, while the average number of circulating shares per person decreased by 2.80% to 19,869 shares [2]. - The company has distributed a total of 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]

Group 1 - Yuheng Pharmaceutical plans to resolve a debt dispute with Qingdao Pusheng Puli Enterprise Management Center regarding the equity transfer payment for Yuheng Biotechnology, which involves a 42.12% stake valued at 117.6 million yuan [1] - Due to Pusheng Puli's failure to pay the agreed amount on time, Yuheng Pharmaceutical initiated legal proceedings in April 2024, which are currently in the execution phase, with no payments received yet [1] - Pusheng Puli intends to transfer 20.64% of its stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., using the proceeds to settle its debt to Yuheng Pharmaceutical [1] Group 2 - November 4 marks the last conversion day for "Nuitai Convertible Bonds," allowing investors to convert their bonds before market close [1] - After November 4, any unconverted "Nuitai Convertible Bonds" will be forcibly redeemed at a price of 100.36 yuan per bond, potentially leading to losses for investors [1]

Core Viewpoint - The company is addressing a debt dispute related to the equity transfer payment of Guangzhou Yuheng Biotechnology Co., Ltd. through an agreement with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) [1] Group 1: Debt Dispute and Legal Proceedings - The lawsuit regarding the equity transfer payment for Yuheng Biotechnology has entered the execution phase, involving multiple complex steps such as equity assessment, judicial auction, transfer, and payment [1] - The process of selling the equity through conventional judicial procedures and recovering the transfer payment is highly uncertain due to difficulties in assessing and pricing the equity [1] Group 2: Equity Transfer - Pusheng Puli intends to transfer its 20.64% stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., with the proceeds being used to repay its debt to the company [1]

Core Viewpoint - The company is addressing a debt dispute related to the equity transfer payment of Guangzhou Yuheng Biotechnology Co., Ltd. through an agreement with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) [1] Group 1: Debt Dispute and Legal Proceedings - The lawsuit regarding the equity transfer payment for Yuheng Biotechnology has entered the execution phase, involving multiple complex steps such as equity assessment, judicial auction, transfer, and payment [1] - The process of selling the equity through conventional judicial procedures and recovering the transfer payment is fraught with significant uncertainty [1] Group 2: Equity Transfer - Pusheng Puli intends to transfer its 20.64% stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., with the proceeds being used to repay its debt to the company [1]

哈尔滨誉衡药业股份有限公司 关于签署《广州誉衡生物科技有限公司之协议书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 哈尔滨誉衡药业股份有限公司（以下简称"公司"）拟通过签署《广州誉衡 生物科技有限公司之协议书》（以下简称"《协议书》"）的方式，解决公司与 青岛普晟普利企业管理中心（有限合伙）（以下简称"普晟普利"）关于广州誉 衡生物科技有限公司（以下简称"誉衡生物"）股权转让款的债务纠纷问题，具 体背景、内容、对公司的影响及风险等情况，公告如下： 一、公司将持有的誉衡生物股权出售给普晟普利的基本情况介绍 2023 年 6 月 28 日、2023 年 7 月 14 日，公司召开的第六届董事会第五次会 议及 2023 年第一次临时股东大会先后审议通过了《关于出售持有的广州誉衡生 物科技有限公司全部股权的议案》，同意公司将持有的誉衡生物 42.12%股权转 让给普晟普利。根据公司与普晟普利签署的《股权转让协议》，普晟普利应向公 司支付的股权转让款为 2.4 亿元。具体内容详见公司 2023 年 6 月 29 日披露于《证 券时报》、《中国证券报》及巨潮资 ...